Multiple Guidelines for iMCD are available to guide treatment decisions1,2
Both the Castleman Disease Collaborative Network (CDCN) and the National Comprehensive Cancer Network® (NCCN®) recommend anti–interleukin 6 therapies as first line treatment options. For more information visit the CDCN or NCCN websites.
Learn more about an FDA approved treatment for idiopathic multicentric Castleman disease that targets IL-6 overproduction.
References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Castleman Disease V.1.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed February 12, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 2. van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115-2124.